Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/214947
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Navarro-pérez, María Pilar | - |
dc.contributor.author | González-quintanilla, Vicente | - |
dc.contributor.author | Muñoz-vendrell, Albert | - |
dc.contributor.author | Madrigal, Elisabet | - |
dc.contributor.author | Alpuente, Alicia | - |
dc.contributor.author | Latorre, Germán | - |
dc.contributor.author | Molina, Francis | - |
dc.contributor.author | Monzón, María José | - |
dc.contributor.author | Medrano, Vicente | - |
dc.contributor.author | García-azorín, David | - |
dc.contributor.author | González-oria, Carmen | - |
dc.contributor.author | Gago-veiga, Ana | - |
dc.contributor.author | Velasco, Fernando | - |
dc.contributor.author | Beltrán, Isabel | - |
dc.contributor.author | Morollón, Noemí | - |
dc.contributor.author | Viguera, Javier | - |
dc.contributor.author | Casas-limón, Javier | - |
dc.contributor.author | Rodríguez-vico, Jaime | - |
dc.contributor.author | Cuadrado, Elisa | - |
dc.contributor.author | Irimia, Pablo | - |
dc.contributor.author | Iglesias, Fernando | - |
dc.contributor.author | Guerrero-peral, Ángel Luis | - |
dc.contributor.author | Belvís, Robert | - |
dc.contributor.author | Pozo-rosich, Patricia | - |
dc.contributor.author | Pascual, Julio | - |
dc.contributor.author | Santos-lasaosa, Sonia | - |
dc.date.accessioned | 2024-09-03T07:50:51Z | - |
dc.date.available | 2024-09-03T07:50:51Z | - |
dc.date.issued | 2024-06-13 | - |
dc.identifier.uri | http://hdl.handle.net/2445/214947 | - |
dc.description.abstract | Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting. Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability. Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects, 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longer-term exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues. Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fneur.2024.1417831 | - |
dc.relation.ispartof | Frontiers in Neurology, 2024, vol. 15 | - |
dc.relation.uri | https://doi.org/10.3389/fneur.2024.1417831 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.title | Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.date.updated | 2024-07-22T08:59:41Z | - |
dc.rights.accessRights | info:eu-repo/semantics/embargoedAccess | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fneur-15-1417831.pdf | 288.5 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.